Beijing PolySeq Technology Co., Ltd. announced that it has received CNY 100 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures
May 11, 2023
Share
On May 12, 2023, Beijing PolySeq Technology Co., Ltd. closed the transaction. The company has amended the terms of the transaction and received CNY 100 million led by new investor Guangzhou Wondfo Biotech Co.,Ltd. The transaction also included participation from other new investors Guangzhou Sanmei Investment Management Center (Limited Partnership), a fund managed by, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, returning investors IDG Capital Partners Co., Ltd., and Tsinghua Innovation Ventures.
GUANGZHOU WONDFO BIOTECH CO., LTD. is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, among others.
Beijing PolySeq Technology Co., Ltd. announced that it has received CNY 100 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures
GUANGZHOU WONDFO BIOTECH CO.,LTD 
